Background: Polycystic ovarian syndrome (PCO) is the most common endocrinopathy in adult women, and is emerging as a common cause of menstrual disturbance in the adolescent population. Insulin resistance, which is considered one of its underlying causes, has increased substantially in the past decade, putting more adolescent girls at risk for PCOS and its complications. Anti Mullerian hormone (AMH) is secreted by the granulose cells of ovarian follicles and correlated with count of small antral follicles and it is expressed throughout folliculogenesis.
Objective: Evaluation of AMH in Egyptian women with PCOS and if it might serve as a prognostic marker for treatment efficacy with metformin.
Patients and methods: The study included 30 women with PCOS (group 1) and 30 healthy women without PCOS (group 2). AMH is measured in both groups and before and after treatment with metformin (2550 mg) for 3 months in group I.
Results: AMH levels was higher in PCO groups before (3.54±0.58 ng/ml) and after treatment (2.79±0.39 ng/ml) than the control group (2.14±0.49 ng/ml) with P<0.01. In PCO group, it was higher before (3.54±0.58 ng/ml) than after treatment (2.79±0.39 ng/ml), with P<0.01.
Conclusion: AMH is higher in PCO subjects and its levels decreases significantly with the insulin sensitizer metformin and it can be used as a marker for treatment efficacy with metformin.
Keywords: PCO, Anti-Mullerian hormone (AMH), Metformin.
20 - 23 May 2017
European Society of Endocrinology